Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM01
- Development stage
- Unknown
- Lead developer
- The Chinese University of Hong Kong
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SIM01 is an orally administered synbiotic microbiome formula developed by The Chinese University of Hong Kong (CUHK) and commercialized by GenieBiome (G-NiiB). It consists of a proprietary blend of three lyophilized food-grade *Bifidobacterium* strains (probiotics) and three prebiotic fibers designed to modulate the gut microbiota. The formula was specifically developed to address gut dysbiosis associated with COVID-19 and "long COVID" (post-acute sequelae of COVID-19), aiming to restore immune balance and alleviate persistent symptoms. Clinical evidence suggests it may also improve vaccine immune responses and liver function in patients with non-alcoholic fatty liver disease (NAFLD).
- Brand names
- G-NiiB Immunity+
- Other names
- G-NiiB Immunity+ Formula SIM01G-NiiB SIM01
Beyond the preview
Go deeper on SIM01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM01.